WALTHAM, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today announced that its financial results for the second quarter of fiscal year 2012 will be released before market open on Thursday, August 9, 2012, followed the same day by a conference call and live webcast scheduled for 8:30 a.m. ET. <\/p>\n
The conference call may be accessed by dialing (877) 845-1016 from the U.S. and Canada, or (708) 290-1155 from international locations. The conference call will also be available via the Internet at http:\/\/www.bg-medicine.com<\/a> <\/p>\n A replay of the call will be available approximately one hour following the end of the call through August 12, 2012. The replay may be accessed by dialing (855) 859-2056 within the U.S. and Canada or (404) 537-3406 from international locations, conference ID # 16463217. The call will be available via webcast from the Investor Relations section of the Company's website at http:\/\/www.bg-medicine.com<\/a>. To listen to the call via the Internet it is recommended that interested parties go to the website prior to the start time to register and install any necessary audio software. <\/p>\n About BG Medicine. <\/p>\n BG Medicine, Inc. (BGMD) is a life sciences company focused on the discovery, development and commercialization of novel, biomarker-based cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http:\/\/www.bg-medicine.com<\/a> and http:\/\/www.galectin-3.com<\/a>. <\/p>\n The BG Medicine Inc. logo is available at http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=10352<\/a> <\/p>\n SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the \"safe harbor\" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as \"believe,\" \"expect,\" \"may,\" \"will,\" \"should,\" \"could,\" \"seek,\" \"intend,\" \"plan,\" \"estimate,\" \"anticipate\" or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recently filed S-1. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. <\/p>\n<\/p>\n Original post: <\/p>\n BG Medicine Announces Second Quarter 2012 Financial Results Release Date and Conference Call Information<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" WALTHAM, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today announced that its financial results for the second quarter of fiscal year 2012 will be released before market open on Thursday, August 9, 2012, followed the same day by a conference call and live webcast scheduled for 8:30 a.m Continue reading